Sunshine Biopharma (SBFM) Total Non-Current Liabilities (2015 - 2026)
Sunshine Biopharma's (SBFM) quarterly Total Non-Current Liabilities came in at $535614.0 in Q1 2026, down 25.84% YoY from $722199.0 in Q1 2025, and down 10.25% on a QoQ basis from $596785.0 in Q4 2025.
Sunshine Biopharma (SBFM) Total Non-Current Liabilities (2015 - 2026) Analysis & Trends
Sunshine Biopharma (SBFM) has 10 years of Total Non-Current Liabilities data on file, last reported at $535614.0 in Q1 2026.
- Quarterly Total Non-Current Liabilities fell 25.84% year-over-year to $535614.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $535614.0 (down 25.84% YoY) and the FY2025 annual result came in at $596785.0, down 19.86% from the prior year.
- Total Non-Current Liabilities fell to $535614.0 in Q1 2026, from $596785.0 in the prior quarter.
- In the past five years, Total Non-Current Liabilities ranged from a high of $744724.0 in Q4 2024 to a low of $489027.0 in Q3 2024.
- A 5-year average of $618336.9 and a median of $617713.5 in 2023 frame the typical range for Total Non-Current Liabilities.
- Annual changes were most pronounced in 2022 — Total Non-Current Liabilities tumbled 63.93% — and 2025, when it jumped 38.09%.
- Tracing SBFM's Total Non-Current Liabilities over 5 years: stood at $685264.0 in 2022, then slipped by 14.23% to $587764.0 in 2023, then advanced by 26.7% to $744724.0 in 2024, then slipped by 19.86% to $596785.0 in 2025, then retreated by 10.25% to $535614.0 in 2026.
- The last three Total Non-Current Liabilities figures came in at $535614.0 (Q1 2026), $596785.0 (Q4 2025), and $636708.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.23 Bn | 43.26 Bn | - | -13.28 Bn |
| 2 | Teva Pharmaceutical Industries | 43.43 Bn | 39.78 Bn | 2.15 Bn | 16.45 Bn |
| 3 | Zoetis | 32.57 Bn | 30.90 Bn | 1.05 Bn | 11.64 Bn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.84 Bn | 5.10 Bn | 33.50 Bn |
| 5 | United Therapeutics | 22.28 Bn | 19.61 Bn | 683.80 Mn | 607.80 Mn |
| 6 | Viatris | 18.85 Bn | 17.96 Bn | 1.46 Bn | 18.76 Bn |
| 7 | Neurocrine Biosciences | 15.51 Bn | 15.12 Bn | 935.80 Mn | 1.37 Bn |
| 8 | Elanco Animal Health | 11.92 Bn | 11.39 Bn | 798.00 Mn | 6.42 Bn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.95 Bn | - | 334.00 Mn |
| 10 | Sunshine Biopharma | 1.56 Mn | -12.19 Mn | 2.43 Mn | 475,820.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 475,820.00 |
| Mar 31, 2026 | 535,614.00 |
| Dec 31, 2025 | 596,785.00 |
| Sep 30, 2025 | 636,708.00 |
| Jun 30, 2025 | 706,530.00 |
| Mar 31, 2025 | 722,199.00 |
| Dec 31, 2024 | 744,724.00 |
| Sep 30, 2024 | 489,027.00 |
| Jun 30, 2024 | 511,635.00 |
| Mar 31, 2024 | 545,697.00 |
| Dec 31, 2023 | 587,764.00 |
| Sep 30, 2023 | 598,719.00 |
| Jun 30, 2023 | 639,882.00 |
| Mar 31, 2023 | 656,168.00 |
| Dec 31, 2022 | 685,264.00 |
| Dec 31, 2021 | 1.90 Mn |
| Mar 31, 2019 | 338,973.00 |
| Dec 31, 2018 | 289,847.00 |
| Dec 31, 2016 | 274,104.00 |
| Dec 31, 2015 | 1.27 Mn |